Monday, June 18, 2007

Sanofi-aventis gets okay to market colorectal cancer drug

From the Globe and Mail:
A drug company has been given the green light by Health Canada to market the long-established colorectal cancer drug oxaliplatin.

Now that Sanofi-aventis Canada Inc. has received its notice of compliance, it alone holds the license to market the drug known by the trade name Eloxatin. The move means three other companies that sold versions of oxaliplatin at deep discount prices under Health Canada's special access program, will have to stop.

“Within the next 4 to 6 weeks we should be able to put [Eloxatin] in the market,” JoĂ«lle Sissmann, vice-president of corporate affairs for Sanofi-aventis Canada Inc., said in a telephone interview from Montreal Monday.

“We got a call this morning that Sanofi had its notice of compliance and we were no longer allowed to sell our product,” Jennifer Wardrop, managing director of Sigmacon Lifesciences Inc., said in a telephone interview Monday. ...more

No comments: